Close this search box.

New CEO for Repligen as Hunt moves to executive chair

ARTICLE | Management Tracks

Plus: BioLoomics hires Gish and an update from Beyond Air

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

June 14, 2024 9:50 PM UTC

Bioprocessing company Repligen Corp. (NASDAQ:RGEN) announced the transition of CEO Tony Hunt to executive chair, effective Sept. 1. President and chief commercial officer (CCO) Olivier Loeillot will become president and CEO, and current Chair Karen Dawes will transition to lead independent director. Loeillot, who will also join the company’s board, served as CEO of Ascensus Specialties LLC for nine months until June 2023.

BioLoomics Inc., which is developing antibody-peptide chimeras, hired Kurt Gish as CSO. Gish was CSO of Trilo Therapeutics Inc., a drug-conjugate company he founded. …